Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1473898 | 1.00 | CXCR4 (0.33) | CXCR4TRPV1 | |
| SCHEMBL1473895 | 0.81 | PDE2A (0.33) | TRPV1 | |
| SCHEMBL1476130 | 0.74 | PDE2A (0.31) | TRPV1 | |
| SCHEMBL12827777 | 0.74 | PDE2A (0.31) | TRPV1 | |
| SCHEMBL12747849 | 0.74 | PDE2A (0.31) | TRPV1 | |
| SCHEMBL1473961 | 0.73 | TRPV1 (0.37) | TRPV1 | |
| SCHEMBL1473706 | 0.73 | TRPV1 (0.33) | TRPV1 | |
| SCHEMBL12827097 | 0.73 | TRPV1 (0.33) | TRPV1 | |
| SCHEMBL12747937 | 0.73 | TRPV1 (0.33) | TRPV1 | |
| SCHEMBL1474971 | 0.72 | TRPV1 (0.43) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915448-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | CNR1, HVCN1, CNR2 | CXCR4 275/4885TRPV1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.